Before you read. This page reproduces what the FDA labels print about switching. It is educational and is not a conversion calculator for your own prescription. Every switch below is a prescribing decision, and the labels state the conversions as instructions to clinicians, not as arithmetic patients can perform. One rule in particular is not optional: taking two semaglutide products at once, or a semaglutide product alongside another GLP-1 receptor agonist, is explicitly not recommended. Do not overlap, and do not start one before your prescriber has stopped the other.
Quick answer
Four switches have a printed conversion in a US label. Everything else people ask about does not.
- Rybelsus ⇄ Ozempic tablets — allowed after the first 30 days, with a two-row conversion table
- Ozempic injection 0.5 mg → Rybelsus tablets — allowed
- Ozempic injection 0.5 mg → Ozempic tablets — allowed, starting a week later
- Wegovy injection ⇄ Wegovy tablets — allowed in both directions, at the top of the ladder
Two details do most of the damage when they are missed. Milligrams do not carry across — the labels say plainly that Rybelsus and Ozempic tablets are not substitutable on a milligram-to-milligram basis, and the same is true of every other pair here. And the gap between stopping and starting depends on the direction: coming off a weekly injection you wait a week, coming off a daily tablet you start the next day.
Why the milligram numbers do not carry across
Start here, because it explains all four tables at once.
Under 1% of a swallowed semaglutide dose reaches the bloodstream. The label puts absolute bioavailability at 0.4% to 1% for Rybelsus and 1% to 2% for Ozempic tablets — a difference of roughly two to threefold between two products containing the same molecule in the same kind of tablet. Why so little of a swallowed dose gets in covers the mechanism.
So the milligram number on a tablet is not a dose in the sense people expect. It is an input to a lossy process, and the loss rate differs by product. What actually matters is the exposure that results, and the label reports that directly:
There were no clinically significant differences observed in the mean steady state AUC and Cmax between the 3 mg, 7 mg and 14 mg doses of RYBELSUS and the 1.5 mg, 4 mg and 9 mg doses of OZEMPIC tablets, respectively, in a clinical study conducted in healthy subjects.
Read that pairing carefully. 3 with 1.5. 7 with 4. 14 with 9. Different numbers on the box, the same amount of drug in the blood. That study is why a conversion table exists at all, and why it looks arbitrary until you know it is there.
Rybelsus ⇄ Ozempic tablets
The label devotes a whole subsection to this one, and it has three rules.
Rule one: not during the first 30 days. The instruction is explicit — do not switch between Rybelsus and Ozempic tablets during the initiation phase, days 1 to 30. That first month is the 3 mg step on Rybelsus and the 1.5 mg step on Ozempic tablets, and the label describes those starting doses as not effective for glycemic control. They exist to let the gut adjust, and switching mid-adjustment restarts a process that has not finished.
Rule two: the conversion is two rows long.
| Rybelsus | Ozempic tablets |
|---|---|
| 7 mg once daily | 4 mg once daily |
| 14 mg once daily | 9 mg once daily |
Note what is absent: the initiation doses are not in the table. There is no 3 mg to 1.5 mg row, because that is the switch rule one forbids.
Rule three: start the day after you stop. The label's phrasing is that the other semaglutide tablet product is initiated the day after discontinuing the previous one. No washout, no gap, no overlap.
That last point surprises people who know semaglutide's one-week half-life and expect a wait. There is no wait because there is nothing to wait for: the two products produce the same exposure at the paired doses, so continuing straight into the equivalent dose keeps the level flat rather than moving it.
Ozempic injection to a tablet
Here the label is narrower than most people expect, and the narrowness is the important part.
Patients taking the 0.5 mg dose of OZEMPIC injection may switch to RYBELSUS tablets.
And separately, for the other tablet:
One week after discontinuing 0.5 mg of subcutaneous OZEMPIC injection, start 4 mg or 9 mg of OZEMPIC tablets orally once daily.
Only the 0.5 mg injection dose is addressed. Ozempic injection is also prescribed at 1 mg and 2 mg. Those doses have no printed tablet conversion, which does not mean the switch never happens — it means the label does not tell you what to switch to, and the decision sits with the prescriber without a printed number behind it.
Notice also the one week between stopping the injection and starting the tablet, against the next day for tablet-to-tablet. That is not inconsistency. A weekly injection given on a Monday is still delivering through the following Sunday; starting a daily tablet on Tuesday would stack the two. A daily tablet's contribution, by contrast, is finished with the day.
A switch is the moment a merged dose list becomes actively confusing. Takely asks which medicine you are on and shows only that medicine's ladder, so the old numbers do not sit next to the new ones. Open Takely in your browser →
Wegovy tablets and Wegovy injection, in both directions
This is the only pair with a printed conversion in both directions, and it is the pair the search traffic asks about most.
The Wegovy tablet ladder runs 1.5 mg, 4 mg, 9 mg, 25 mg, thirty days at each step, with 25 mg once daily as the maintenance dose.
Injection to tablets. Patients on Wegovy 2.4 mg injection may switch to Wegovy 25 mg tablets. One week after discontinuing the injection, the 25 mg tablet is started once daily.
Tablets to injection. The day after discontinuing 25 mg tablets, Wegovy 2.4 mg subcutaneous injection is started once weekly. The label adds two branches: for patients who do not tolerate the 25 mg tablet, consider switching to the 1.7 mg injection instead; and if additional weight reduction is needed in patients with type 2 diabetes on the 25 mg tablet, consider the 1.7 mg injection and then follow the injection's own escalation.
The same asymmetry appears again — a week off the injection, a day off the tablet — and for the same reason.
What is worth noticing is that both conversions live at the top of each ladder. The printed switch is between the maintenance dose of one form and the maintenance dose of the other. There is no conversion table for someone three weeks into the tablet ladder wanting to move across, because the label does not offer mid-ladder equivalences. What changes day to day between the pill and the shot covers the practical differences behind that choice.
Every printed conversion, in one table
| From | To | What the label says | Gap before starting |
|---|---|---|---|
| Rybelsus 7 mg | Ozempic tablets 4 mg | Allowed after the initiation phase | Next day |
| Rybelsus 14 mg | Ozempic tablets 9 mg | Allowed after the initiation phase | Next day |
| Ozempic tablets 4 or 9 mg | Rybelsus 7 or 14 mg | Same table, read the other way | Next day |
| Rybelsus 3 mg or Ozempic tablets 1.5 mg | Either | Not during days 1 to 30 | — |
| Ozempic injection 0.5 mg | Rybelsus tablets | Allowed | Not specified in the sentence |
| Ozempic injection 0.5 mg | Ozempic tablets 4 or 9 mg | Allowed | One week |
| Wegovy injection 2.4 mg | Wegovy tablets 25 mg | Allowed | One week |
| Wegovy tablets 25 mg | Wegovy injection 2.4 mg | Allowed; 1.7 mg if 25 mg was not tolerated | Next day |
Everything not in that table has no printed conversion. That is the honest boundary of what a label can tell you.
The switches no label covers
These come up constantly and deserve a straight answer rather than an improvised one.
Rybelsus to Wegovy tablets, or the reverse. Both are oral semaglutide. Neither label prints a conversion to the other, because they are different products with different indications and different ladders — one goes to 14 mg for glycemic control, the other to 25 mg. One molecule, two prescriptions covers why they are separate products at all.
Anything to or from Foundayo. Orforglipron is a different molecule with its own six-step ladder and no fasting requirement, and there is no cross-molecule conversion anywhere. The six-step Foundayo ladder is its own sequence, started from the bottom.
Anything to or from tirzepatide. Different molecule again, and a dual receptor agonist rather than a GLP-1 receptor agonist alone.
Ozempic injection 1 mg or 2 mg to any tablet. As above: the label addresses 0.5 mg and stops.
The rule that covers all of these is in the Wegovy label's Limitations of Use, and it is the one part of this page to treat as absolute:
Concomitant use of WEGOVY tablets or WEGOVY injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.
Whatever the switch, the two do not overlap.
What actually changes about your day
A conversion table hides the part you will notice, which is not the milligrams.
Going from an injection to a tablet adds a morning. The pen has no food rule at all — a subcutaneous injection does not care what you had for breakfast. The tablet does: empty stomach, morning, up to 4 ounces of plain water and nothing else to drink, swallowed whole, then at least 30 minutes before food, other drinks or other oral medicines. That is a new daily constraint, and the 30-minute wait, step by step is where mornings actually break.
Going from a tablet to an injection removes it. One event a week, no window, no wait. People who found the window unworkable often find this is the whole reason the switch was suggested.
Going tablet to tablet changes almost nothing except the number on the box — which is precisely why it is worth writing the new number down. A ladder you half-remember from a different product is the most common way a dose gets taken wrong after a switch, and a per-drug ladder rather than one merged list is the small thing that prevents it.
What to ask before switching
Four questions, and they map onto the four things the labels leave to a prescriber.
"What dose am I starting on, exactly?" Not the equivalent, the number. Write it down in the room.
"What day do I start it?" The day after, or a week later, depending on the direction. This is the detail most likely to be assumed rather than said.
"Do I restart the ladder?" For the switches with a printed conversion, generally no. For everything else, generally yes — and it is a question, not an inference.
"What happens to my other medicines?" If you take insulin or a sulfonylurea, their doses may have been set around the current drug. And on any oral GLP-1 the 30-minute window applies to your other tablets too, which is a change of routine an injection did not impose.
Frequently asked questions
Can I switch from Rybelsus to Ozempic tablets?
Yes, after the initiation phase. The label says not to switch during days 1 to 30, and that after 30 days patients may switch, starting the other product the day after discontinuing the first. The conversion is 7 mg to 4 mg, or 14 mg to 9 mg.
Is 14 mg of Rybelsus the same as 9 mg of Ozempic tablets?
In exposure, effectively yes — the label reports no clinically significant differences in steady-state exposure between those paired doses in healthy subjects, which is why they appear on the same row of the switching table. In milligrams, no, and the label states in its dosage section that the two products are not substitutable on a milligram-to-milligram basis.
How do I convert the Wegovy pill to the Wegovy injection?
The label pairs the 25 mg tablet with the 2.4 mg once-weekly injection, started the day after the last tablet. For patients who did not tolerate the 25 mg tablet it suggests considering the 1.7 mg injection instead. Going the other way, the 25 mg tablet is started one week after the last 2.4 mg injection.
Can I switch from an Ozempic injection to Rybelsus?
The label addresses the 0.5 mg injection dose and says patients taking it may switch to Rybelsus tablets. It does not print a conversion from the 1 mg or 2 mg injection doses.
Why do I wait a week coming off the injection but start the next day coming off the tablet?
Because a weekly injection is still being absorbed for days after it is given, while a daily tablet's contribution ends with that day. The waiting period is there to avoid stacking two sources of the same drug, not to clear it — semaglutide's half-life is about a week either way.
Do I have to start the dose ladder again after switching?
Not for the switches with a printed conversion; those move you across at an equivalent dose. For switches with no printed conversion, including any change of molecule, the new drug's own ladder is the starting point. Either way it is a prescribing decision rather than something to infer from a chart.
Primary sources and further reading
- FDA Prescribing Information — RYBELSUS (semaglutide) tablets and OZEMPIC (semaglutide) tablets, sections 2.1, 2.2, 2.3, 2.4 and 12.3 ↗
- FDA Prescribing Information — WEGOVY (semaglutide) injection and WEGOVY (semaglutide) tablets, Limitations of Use and sections 2.2, 2.3 and 2.5 ↗
- FDA label via DailyMed — FOUNDAYO (orforglipron) tablets, section 2 ↗
Labels are revised without notice and conversion tables are exactly the kind of detail that changes. Everything above was read off those documents on 8 September 2026.